Endologix (ELGX) 10-Q 29 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Oct. 29, 2014
Document and Entity Information [Abstract]
Entity Registrant Name	ENDOLOGIX INC /DE/
Entity Central Index Key	1013606
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		67,418,357
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Current assets:
Cash and cash equivalents	$20,183		$26,798
Marketable securities	53,467		59,871
Accounts receivable, net allowance for doubtful accounts of $182 and $185, respectively.	26,672		26,113
Other receivables	448		498
Inventories	35,143		31,325
Prepaid expenses and other current assets	2,501		3,162
Total current assets	138,414		147,767
Property and equipment, net	25,329		25,696
Goodwill	28,673	[1]	28,866	[1]
Intangibles, net	43,067		43,465
Deposits and other assets	2,282		2,415
Total assets	237,765		248,209
Current liabilities:
Accounts payable	11,130		11,027
Accrued payroll	10,916		13,337
Accrued expenses and other current liabilities	5,403		5,260
Total current liabilities	27,449		29,624
Deferred income tax	879		879
Deferred rent	8,047		8,060
Other liabilities	419		489
Contingently issuable common stock	14,700		14,600
Convertible notes	71,270		70,407
Total liabilities	122,764		124,059
Commitments and contingencies
Stockholders’ equity:
Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized. No shares issued and outstanding.	0		0
Common stock, $0.001 par value; 100,000,000 shares authorized. 67,579,721 and 67,321,769 shares issued, respectively. 67,415,229 and 67,159,511 shares outstanding, respectively.	67		67
Treasury stock, at cost, 164,492 and 162,258 shares, respectively.	-2,363		-2,328
Additional paid-in capital	376,492		372,639
Accumulated deficit	-259,713		-248,500
Accumulated other comprehensive income	518		2,272
Total stockholders’ equity	115,001		124,150
Total liabilities and stockholders’ equity	$237,765		$248,209
[1]	Difference in the value between these dates is solely due to a foreign currency translation adjustment.

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Allowance for doubtful accounts	$182	$185
Common stock, par value (per share)	$0.00	$0.00
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	67,579,721	67,321,769
Common stock, shares outstanding	67,415,229	67,159,511
Treasury stock, shares	164,492,000	162,258,000
Convertible Preferred Stock
Convertible preferred stock, par value (per share)	$0.00	$0.00
Convertible preferred stock, shares authorized	5,000,000	5,000,000
Convertible preferred stock, shares issued	0	0
Convertible preferred stock, shares outstanding	0	0

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Revenue	$36,671	$33,264
Cost of goods sold	9,765	8,969
Gross profit	26,906	24,295
Operating expenses:
Research and development	6,231	4,105
Clinical and regulatory affairs	3,450	2,200
Marketing and sales	19,599	16,143
General and administrative	7,289	7,163
Total operating expenses	36,569	29,611
Loss from operations	-9,663	-5,316
Other income (expense):
Interest income	45	59
Interest expense	-1,462	-1,390
Other income (expense), net	59	358
Change in fair value of contingent consideration related to acquisition	-100	11,800
Total other income (expense)	-1,458	10,827
Net income (loss) before income tax expense	-11,121	5,511
Income tax expense	-92	-216
Net income (loss)	-11,213	5,295
Other comprehensive loss- foreign currency translation	-1,754	-46
Comprehensive income (loss)	($12,967)	$5,249
Basic net income (loss) per share	($0.17)	$0.08
Diluted net income (loss) per share	($0.17)	$0.08
Shares used in computing basic net income (loss) per share	67,263,000	63,405,000
Shares used in computing diluted net income (loss) per share	67,263,000	66,017,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income (loss)	($11,213)	$5,295
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation and amortization	1,489	602
Stock-based compensation	2,211	1,613
Change in fair value of contingent consideration related to acquisition	100	-11,800
Accretion of interest on convertible note	863	800
Amortization of deferred financing costs	113	97
Non-cash foreign exchange loss (gain)	111	-367
Changes in operating assets and liabilities:
Accounts receivable and other receivables	48	-254
Inventories	-4,637	-4,360
Prepaid expenses and other current assets	681	-147
Accounts payable	859	4,005
Accrued payroll	-2,482	-1,654
Accrued expenses and other liabilities	130	3,190
Net cash used in operating activities	-11,727	-2,980
Cash flows from investing activities:
Purchases of marketable securities	-28,059	-53,023
Maturities of marketable securities	34,430	6,918
Purchases of property and equipment	-2,174	-3,491
Net cash provided by (used in) investing activities	4,197	-49,596
Cash flows from financing activities:
Proceeds from exercise of stock options	1,642	246
Minimum tax withholding paid on behalf of employees for restricted stock units	-35	-644
Net cash provided by (used in) financing activities	1,607	-398
Effect of exchange rate changes on cash and cash equivalents	-692	1
Net decrease in cash and cash equivalents	-6,615	-52,973
Cash and cash equivalents, beginning of period	26,798	95,152
Cash and cash equivalents, end of period	20,183	42,179
Supplemental disclosure of cash flow information:
Cash paid for income taxes	35	129
Non-cash investing and financing activities:
Landlord funded leasehold improvements	0	2,425
Acquisition of property and equipment included in accounts payable	$1,254	$0

Description_of_Business_Basis_

Description of Business, Basis of Presentation, and Operating Segment	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Basis of Presentation, and Operating Segment	Description of Business, Basis of Presentation, and Operating Segment
	(a) Description of Business
	Endologix, Inc. (the "Company") is a Delaware corporation with corporate headquarters and production facilities located in Irvine, California. The Company develops, manufactures, markets, and sells innovative medical devices for the treatment of aortic disorders. The Company's products are intended for the treatment of abdominal aortic aneurysms ("AAA"). The Company's AAA products are built on one of two platforms: (1) traditional minimally-invasive endovascular repair ("EVAR") or (2) endovascular sealing (“EVAS”), the Company's innovative solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The Company's current EVAR products include the Endologix AFX Endovascular AAA System (“AFX”), the VELA Proximal Endograft (“VELA”) and the Endologix Intuitrak Endovascular AAA System (“Intuitrak”). The Company's current EVAS product is the Nellix Endovascular Aneurysm Sealing System (“Nellix EVAS System”). Sales of the Company's EVAR and EVAS platforms (including extensions and accessories) to hospitals in the U.S. and Europe, and to third-party international distributors, provide the sole source of the Company's reported revenue.
	The Company's EVAR products consist of (i) a cobalt chromium alloy stent covered by polytetrafluoroethylene (commonly referred to as "ePTFE") graft material (“Stent Graft”) and (ii) an accompanying delivery system. Once fixed in its proper position within the abdominal aorta, the Company's EVAR device provides a conduit for blood flow, thereby relieving pressure within the weakened or “aneurysmal” section of the vessel wall, which greatly reduces the potential for the AAA to rupture.
	The Company's EVAS product consists of (i) bilateral covered stents with endobags, (ii) a biocompatible polymer injected into the endobags to seal the aneurysm and (iii) a delivery system and polymer dispenser. The Company's EVAS product seals the entire aneurysm sac effectively excluding the aneurysm sac reducing the likelihood of future aneurysm rupture. Additionally, it has the potential to reduce post procedural re-interventions.
	(b) Basis of Presentation
	The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the three months ended March 31, 2015 and 2014, there were no related party transactions.
	The interim financial data as of March 31, 2015 is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three months ended March 31, 2015. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements.
	The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 2, 2015.
	On May 28, 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU ") No. 2014-09, "Revenue from Contracts with Customers", which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The new standard is effective for the Company on January 1, 2017. Early application is not permitted. The standard permits the use of either the retrospective or cumulative effect transition method. On April 1, 2015 the FASB agreed to propose a one-year deferral of the revenue recognition standard's effective date for all entities. Early application would be permitted, but not before the original effective date. The option to use either a retrospective or cumulative-effective transition method would not change. The Company is evaluating the effect that ASU 2014-09 will have on its consolidated financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.
	On April 7, 2015, the FASB issued ASU No. 2015-03, "Simplifying the Presentation of Debt Issuance Costs", which requires debt issuance costs related to a recognized debt liability to be presented on the balance sheet as a direct deduction from the debt liability, similar to the presentation of debt discounts. The ASU is effective for the Company on January 1, 2016. Early adoption is permitted. The Company is evaluating the effect that ASU 2015-03 will have on its consolidated financial statements and related disclosures.
	(c) Operating Segment
	The Company has one operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the three months ended March 31, 2015, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.

Use_of_Estimates_and_Summary_o

Use of Estimates and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Accounting Policies [Abstract]
Use of Estimates and Summary of Significant Accounting Policies	Use of Estimates and Summary of Significant Accounting Policies
	The preparation of financial statements in conformity with GAAP requires the Company's management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, and related disclosure of contingent liabilities. On an on-going basis, the Company's management evaluates its estimates, including those related to (i) collectibility of customer accounts; (ii) whether the cost of inventories can be recovered; (iii) the value of goodwill and intangible assets; (iv) realization of tax assets and estimates of tax liabilities; (v) likelihood of payment and value of contingent liabilities; and (vi) potential outcome of litigation. Such estimates are based on management's judgment which takes into account historical experience and various assumptions. Nonetheless, actual results may differ from management's estimates.
	For a complete summary of our significant accounting policies, please refer to Note 2, "Use of Estimates and Summary of Significant Accounting Policies", in Part II, Item 8, of our 2014 Annual Report on Form 10-K for the year ended December 31, 2014, filed March 2, 2015. There have been no material changes to our significant accounting policies during the three months ended March 31, 2015.

Balance_Sheet_Account_Detail

Balance Sheet Account Detail	3 Months Ended
	Mar. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Balance Sheet Account Detail	Balance Sheet Account Detail
	(a) Property and Equipment
	Property and equipment consisted of the following:
		March 31,			December 31,
		2015			2014
	Production equipment, molds, and office furniture	$	13,560		$	12,943
	Computer hardware and software	6,504			6,457
	Leasehold improvements	16,251			15,729
	Construction in progress (software and related implementation, production equipment, and leasehold improvements)	1,188			2,564
	Property and equipment, at cost	$	37,503		$	37,693
	Accumulated depreciation	(12,174		)	(11,997		)
	Property and equipment, net	$	25,329		$	25,696
	Depreciation expense for property and equipment for the three months ended March 31, 2015 and 2014 was $1.1 million, and $0.5 million, respectively.
	(b) Inventories
	Inventories consisted of the following:
		March 31,			December 31,
		2015			2014
	Raw materials	$	8,161		$	6,728
	Work-in-process	7,372			5,946
	Finished goods	19,610			18,651
	Total Inventories	$	35,143		$	31,325
	(c) Goodwill and Intangible Assets
	The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets, and related accumulated amortization:
		March 31,			December 31,
		2015			2014
	Goodwill (1)	$	28,673		$	28,866
	Intangible assets:
	Indefinite lived intangibles
	Trademarks and trade names	$	2,708		$	2,708
	Finite lived intangibles
	Developed technology (2)	$	40,100		$	40,100
	Accumulated amortization	(382		)	(285		)
	Developed technology, net	$	39,718		$	39,815
	License	$	100		$	100
	Accumulated amortization	(78		)	(71		)
	License, net	$	22		$	29
	Customer relationships (1)	$	429		$	480
	Accumulated amortization (1)	(393		)	(400		)
	Customer relationships, net	$	36		$	80
	Acquired Shonin approval (3)	$	1,000		$	1,000
	Accumulated amortization	(417		)	(167		)
	Acquired Shonin approval, net	$	583		$	833
	Intangible assets (excluding goodwill), net	$	43,067		$	43,465
	(1) Difference in the value between these dates is solely due to a foreign currency translation adjustment.
	(2) Was reclassified in the first quarter of 2013 from in-process research and development to finite lived intangibles, which coincided with the European commercial launch of the product (Nellix EVAS System) associated with this intangible asset. A significant portion of this intangible asset will not begin amortization until the U.S. launch of this product, currently scheduled for 2016.
	(3) Regulatory approval for Intuitrak in Japan acquired through an amendment with a distributor in the fourth quarter of 2014.
	Amortization expense for intangible assets for the three months ended March 31, 2015, and 2014 was $0.4 million, and $0.1 million respectively.
	Estimated amortization expense for the five succeeding years and thereafter (which includes amortization of intangible assets which commenced in February 2013 with the commercial launch of the Nellix System in Europe) is as follows:
	Remainder of 2015	$	931
	2016	948
	2017	2,210
	2018	3,689
	2019	4,744
	2020	5,409
	2021 & Thereafter	22,428
	Total	$	40,359
	(d) Marketable securities
	Investments in held-to-maturity marketable securities consist of the following at March 31, 2015 and December 31, 2014:
		31-Mar-15
		Amortized			Gross			Gross			Fair Value
		Cost			Unrealized			Unrealized
					Gain			Loss
	Asset backed securities	$	1,473		$	—		$	—		$	1,473
	Agency bonds	3,000			—			(1		)	2,999
Corporate bonds	5,669			—			(2		)	5,667
Commercial paper	40,281			7			—			40,288
Government securities	3,044			—			—			3,044
Total	$	53,467		$	7		$	(3	)	$	53,471
	31-Dec-14
	Amortized			Gross			Gross			Fair Value
	Cost			Unrealized			Unrealized
				Gain			Loss
Asset backed securities	$	3,633		$	—		$	—		$	3,633
Corporate bonds	15,707			—			(8		)	15,699
Commercial paper	40,531			5			—			40,536
Total	$	59,871		$	5		$	(8	)	$	59,868
At March 31, 2015, the Company’s investments included 8 held-to-maturity debt securities in unrealized loss positions with a total unrealized loss of approximately $3,000 and a total fair market value of approximately $11.2 million. All investments with gross unrealized losses have been in unrealized loss positions for less than 12 months. The unrealized losses were caused by interest rate fluctuations. There was no change in the credit risk of the securities. The Company does not intend to sell the securities and it is not likely that the Company will be required to sell the securities before the expected recovery of their amortized cost bases. There were no realized gains or losses on the investments for the three months ended March 31, 2015. Investments of held-to-maturity all mature within less than 12 months with an average maturity of 4 months.
(e) Fair Value Measurements
The following fair value hierarchy table presents information about each major category of the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
	Fair value measurement at reporting date using:
	Quoted prices in			Significant other			Significant			Total
	active markets for			observable			unobservable
	identical assets			inputs			inputs
	(Level 1)			(Level 2)			(Level 3)
At March 31, 2015
Cash and cash equivalents	$	20,183		$	—		$	—		$	20,183
Contingently issuable common stock	$	—		$	—		$	14,700		$	14,700
At December 31, 2014
Cash and cash equivalents	$	26,798		$	—		$	—		$	26,798
Contingently issuable common stock	$	—		$	—		$	14,600		$	14,600
There were no re-measurements to fair value during the three months ended March 31, 2015 of financial assets and liabilities that are not measured at fair value on a recurring basis. There were no transfers between Level 1, Level 2, or Level 3 securities during the three months ended March 31, 2015.
(f) Financial Instruments Not Recorded at Fair Value on a Recurring Basis
We measure the fair value of our Senior Notes carried at amortized cost quarterly for disclosure purposes. The estimated fair value of the Senior Notes is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar issues. Based on the market prices, the fair value of our long-term debt was $87.8 million as of March 31, 2015 and $84.5 million as of December 31, 2014.
We measure the fair value of our held-to-maturity marketable securities carried at amortized cost quarterly for disclosure purposes. The fair value of marketable securities is determined by Level 2 inputs and is based primarily on quoted market prices for the same or similar instruments.

StockBased_Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation
	The Company classifies stock-based compensation expense in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Income (Loss), based on the department to which the recipient belongs. Stock-based compensation expense included in cost of goods sold and operating expenses during the three months ended March 31, 2015 and 2014, was as follows:
		Three Months Ended
		March 31,
		2015		2014
	Cost of goods sold	$	248	$	208
	Operating expenses:
	Research and development	228		161
	Clinical and regulatory affairs	185		(103		)
	Marketing and sales	749		538
	General and administrative	801		809
	Total operating expenses	$	1,963	$	1,405
	Total	$	2,211	$	1,613

Net_Income_Loss_Per_Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Net Income (Loss) Per Share
	Basic net income (loss) per share was calculated by dividing net income (loss) by the weighted average number of common shares outstanding for the three months ended March 31, 2015 and 2014. Diluted net income per share for the three months ended March 31, 2014, was calculated by adjusting outstanding shares for the dilutive effects of outstanding, but unexercised, stock options and unvested restricted stock, as calculated under the treasury stock method.
		Three Months Ended
		March 31,
		2015				2014
	Net income (loss)	$	(11,213	)		$	5,295
	Weighted average shares- basic	67,263				63,405
	Weighted average shares- diluted	67,263				66,017
	Net income (loss) per share- basic	$	(0.17	)		$	0.08
	Net income (loss) per share- diluted	$	(0.17	)		$	0.08
	The following outstanding Company securities were included in the above calculations of net income per share because their impact was dilutive:
		Three Months Ended
		March 31,
		2015			2014
	Common stock options	—			2,027
	Restricted stock awards	—			152
	Restricted stock units	—			433
	Total	—			2,612
	The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net income loss per share because their impact would have been anti-dilutive:
		Three Months Ended
		March 31,
		2015			2014
	Common stock options	1,813			1,153
	Restricted stock awards	135			—
	Restricted stock units	234			—
	Total	2,182			1,153
	As discussed in Note 6, in December 2013, the Company issued $86.3 million aggregate principal amount of 2.25% convertible senior notes due 2018 (the “Notes”) in an underwritten public offering. Upon any conversion, the Notes may be settled, at the Company’s election, in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. For purposes of calculating the maximum dilutive impact, it is presumed that the Notes will be settled in common stock with the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. The effect of the conversion of the Notes is excluded from the calculation of diluted income (loss) per share because the impact of these securities would be anti-dilutive. The potential dilutive effect of these securities is shown in the chart below:
		Three Months Ended
		March 31,
		2015			2014
	Conversion of the Notes	3,588			3,588
	The effect of the contingently issuable common stock is excluded from the calculation of basic net income (loss) per share until all necessary conditions for issuance have been satisfied. Refer to Note 9 of the Notes to the Condensed Consolidated Financial Statements for further discussion.

Credit_Facilities

Credit Facilities	3 Months Ended
	Mar. 31, 2015
Line of Credit Facility [Abstract]
Credit Facilities	Credit Facilities
	2.25% Convertible Senior Notes
	On December 10, 2013, the Company issued $86.3 million aggregate principal amount 2.25% Convertible Senior Notes (the “Notes”). The Notes mature on December 15, 2018 unless earlier repurchased by the Company or converted. The Company received net proceeds from the sale of the Notes of approximately $82.6 million, after deducting underwriting discounts and commissions and offering expenses payable by the Company. Interest is payable on the Notes on June 15 and December 15 of each year, beginning June 15, 2014.
	The Notes are governed by the terms of a base indenture (the “Base Indenture”), as supplemented by the first supplemental indenture relating to the Notes (the “First Supplemental Indenture,” and together with the Base Indenture, the “Indenture”), between the Company and Wells Fargo Bank, National Association (the “Trustee”), each of which were entered into on December 10, 2013.
	The Notes are senior unsecured obligations and are: senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the Notes; equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated; effectively junior to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries.
	The Company may not redeem the Notes prior to December 15, 2016. On or after December 15, 2016, the Company may redeem for cash all or any portion of the Notes, at its option, but only if the closing sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period ending on, and including, the second trading day immediately preceding the date on which the Company provides notice of redemption, exceeds 130% of the conversion price on each applicable trading day. The redemption price will equal 100% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the Notes.
	Holders may convert their Notes at any time prior to the close of business on the business day immediately preceding September 15, 2018 only under the following circumstances: (1) during any calendar quarter commencing after the calendar quarter ending on March 31, 2014, if the closing sale price of the Company’s common stock, for at least 20 trading days (whether or not consecutive) in the period of 30 consecutive trading days ending on the last trading day of the calendar quarter immediately preceding the calendar quarter in which the conversion occurs, is more than 130% of the conversion price of the Notes in effect on each applicable trading day; (2) during the five consecutive business-day period following any five consecutive trading-day period in which the trading price for the Notes for each such trading day was less than 98% of the closing sale price of the Company’s common stock on such date multiplied by the then-current conversion rate; (3) if the Company calls all or any portion of the notes for redemption, at any time prior to the close of business on the second scheduled trading day prior to the redemption date; or (4) upon the occurrence of specified corporate events. On or after September 15, 2018 until the close of business on the second scheduled trading day immediately preceding the stated maturity date, holders may surrender their Notes for conversion at any time, regardless of the foregoing circumstances.
	Upon conversion, the Company will, at its election, pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock.
	The initial conversion rate will be 41.6051 shares of the Company’s common stock for each $1,000 principal amount of Notes, which represents an initial conversion price of approximately $24.04 per share. Following certain corporate transactions that occur on or prior to the stated maturity date or the Company’s delivery of a notice of redemption, the Company will increase the conversion rate for a holder that elects to convert its Notes in connection with such a corporate transaction.
	If a fundamental change (as defined in the Indenture) occurs prior to the stated maturity date, holders may require the Company to purchase for cash all or any portion of their Notes at a fundamental change purchase price equal to 100% of the principal amount of the Notes to be purchased, plus accrued and unpaid interest to, but excluding, the fundamental change purchase date.
	The Indenture contains customary terms and covenants and events of default with respect to the Notes. If an event of default (as defined in the Indenture) occurs and is continuing, either the Trustee or the holders of at least 25% in aggregate principal amount of the outstanding Notes may declare the principal amount of the Notes to be due and payable immediately by notice to the Company (with a copy to the Trustee). If an event of default arising out of certain events of bankruptcy, insolvency or reorganization involving the Company or a significant subsidiary (as set forth in the Indenture) occurs with respect to us, the principal amount of the Notes and accrued and unpaid interest, if any, will automatically become immediately due and payable.
	The Company was not required to separate the conversion option in the Notes under ASC 815, "Derivatives and Hedging", and has the ability to settle the Notes in cash, common stock or a combination of cash and common stock, at its option. In accordance with cash conversion guidance contained in ASC 470-20, "Debt with Conversion and Other Options", the Company accounted for the Notes by allocating the issuance proceeds between the liability and the equity component. The equity component is classified in stockholders’ equity and the resulting discount on the liability component is accreted such that interest expense equals the Company’s nonconvertible debt borrowing rate. The separation was performed by first determining the fair value of a similar debt that does not have an associated equity component. That amount was then deducted from the initial proceeds of the Notes as a whole to arrive at a residual amount, which was allocated to the conversion feature that is classified as equity. The initial fair value of the indebtedness was $66.9 million resulting in a $19.3 million allocation to the embedded conversion option. The embedded conversion option was recorded in stockholders’ equity and as debt discount, to be subsequently accreted to interest expense over the term of the Notes. Underwriting discounts and commissions and offering expenses totaled $3.7 million and were allocated between the liability and the equity component in proportion to the allocation of proceeds and accounted for as debt issuance costs and equity issuance costs, respectively. As a result, $2.9 million attributable to the indebtedness was recorded as deferred financing costs in other assets, to be subsequently amortized as interest expense over the term of the Notes, and $0.8 million attributable to the equity component was recorded a a reduction to additional paid-in-capital in stockholders’ equity.
	As of March 31, 2015, the Company had outstanding borrowings of $71.3 million, and deferred financing costs of $2.3 million, related to the Notes. There are no principal payments due during the term. Annual interest expense on these notes will range from $5.7 million to $6.9 million through maturity.
	Capped Call Transactions
	On December 10, 2013, in connection with the pricing of the Notes and the exercise in full of their overallotment option by the underwriters, the Company entered into privately-negotiated capped call transactions (the “Capped Call Transactions”) with Bank of America, N.A., an affiliate of Merrill Lynch, Pierce, Fenner & Smith Incorporated. The Capped Call Transactions initial conversion rate and number of options substantially corresponds to each $1,000 principal amount of Notes. The Company used approximately $7.4 million of the net proceeds from the Notes offering to pay for the cost of the Capped Call Transactions.
	The Capped Call Transactions are separate transactions entered into by the Company with Bank of America, N.A., are not part of the terms of the Notes and will not change the holders’ rights under the Notes. The Capped Call Transactions have anti-dilution adjustments substantially similar to those applicable to the Notes. The Capped Call Transactions are derivative instruments that are recorded within stockholders’ equity because they meet an exemption from mark-to-market derivative accounting.
	The Capped Call Transactions are expected generally to reduce the potential dilution and/or offset potential cash payments that the Company is required to make in excess of the principal amount upon conversion of the Notes in the event that the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions, which initially corresponds to the $24.04 conversion price of the Notes. If, however, the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the initial cap price of $29.02, there would nevertheless be dilution and/or there would not be an offset of such potential cash payments, in each case, to the extent that such market price exceeds the cap price of the Capped Call Transactions.
	The Company will not be required to make any cash payments to Bank of America, N.A. or any of its affiliates upon the exercise of the options that are a part of the Capped Call Transactions, but will be entitled to receive from Bank of America, N.A. (or an affiliate thereof) a number of shares of the Company’s common stock and/or an amount of cash generally based on the amount by which the market price per share of the Company’s common stock, as measured under the terms of the Capped Call Transactions, is greater than the strike price of the Capped Call Transactions during the relevant valuation period under the Capped Call Transactions. However, if the market price of the Company’s common stock, as measured under the terms of the Capped Call Transactions, exceeds the cap price of the Capped Call Transactions during such valuation period under the Capped Call Transactions, the number of shares of common stock and/or the amount of cash the Company expects to receive upon exercise of the Capped Call Transactions will be capped based on the amount by which the cap price exceeds the strike price of the Capped Call Transactions.
	For any conversions of Notes prior to the close of business on the 55th scheduled trading day immediately preceding the stated maturity date of the Notes, including without limitation upon an acquisition of the Company or similar business combination, a corresponding portion of the Capped Call Transactions will be terminated. Upon such termination, the portion of the Capped Call Transactions being terminated will be settled at fair value (subject to certain limitations), as determined by Bank of America, N.A., in its capacity as calculation agent under the Capped Call Transactions, which the Company expects to receive from Bank of America, N.A., and no payments will be due Bank of America, N.A. The capped call expires on December 13, 2018.
	Wells Fargo line of credit
	In October 2009, the Company entered into a revolving credit facility with Wells Fargo Bank (“Wells”), which was last amended on February 3, 2015, whereby the Company may borrow up to $20.0 million, subject to the calculation and limitation of a borrowing base (the “Wells Credit Facility”). All amounts owing under the Wells Credit Facility will become due and payable upon its expiration on November 15, 2015. A sub-feature in the line of credit allows for the issuance of up to $7.5 million in letters of credit. As of March 31, 2015, the Company had no outstanding letters of credit issued. The Wells Credit Facility is collateralized by all of the Company's assets, except its intellectual property.
	The Wells Credit Facility contains financial covenants requiring the Company to (i) maintain a minimum current ratio of 2.0, equal to the quotient of modified current assets to current liabilities, as defined in the Wells Credit Facility (the "Current Ratio Covenant"), and (ii) not to exceed pre-tax net loss (excluding non-cash contingent consideration associated with the acquisition of Nellix) of $13.5 million for the three months ended March 31, 2015; $23.0 million for the six months ended June 30, 2015; and $35.0 million for the nine months ended September 30, 2015; (the "Net Loss Covenant").  The Wells Credit Facility also includes negative covenants limiting capital expenditures in 2015 to an aggregate of $6.0 million as well as limiting operating lease expenses to $3.0 million in any calendar year. The Company was in compliance with the financial covenants as of and for the three months ended March 31, 2015.
	The Wells Credit Facility also contains a “material adverse change” clause (“MAC”). If the Company encounters difficulties that would qualify as a MAC in its (i) operations, (ii) condition (financial or otherwise), or (iii) ability to repay amounts outstanding under the Wells Credit Facility, it could be canceled at Wells' sole discretion. Wells could then elect to declare the indebtedness, together with accrued interest and other fees, to be immediately due and payable and proceed against any collateral securing such indebtedness. No borrowings were outstanding at March 31, 2015.

Revenue_by_Geographic_Region

Revenue by Geographic Region	3 Months Ended
	Mar. 31, 2015
Geographic Areas, Revenues from External Customers [Abstract]
Revenue by Geographic Region	Revenue by Geographic Region
	The Company's revenue by geographic region, was as follows:
		Three Months Ended
		March 31,
		2015			2014
	United States	$	25,134	68.50%	$	23,988	72.10%
	Europe	$	7,246	19.80%	$	6,585	19.80%
	Rest of World ("ROW"):
	Latin America	$	2,039	5.60%	$	918	2.80%
	Asia/Pacific	2,252		6.10%	1,773		5.30%
	Total ROW	$	4,291	11.70%	$	2,691	8.10%
	Revenue	$	36,671	100.00%	$	33,264	100.00%

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	(a) Leases
	The Company leases its administrative, research, and manufacturing facilities located in Irvine, California and an administrative office located in Rosmalen, The Netherlands. These facility lease agreements require the Company to pay operating costs, including property taxes, insurance, and maintenance. In addition, the Company has certain equipment under long-term agreements that are accounted for as operating leases.
	Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of March 31, 2015:
	Remainder of 2015	$	1,909
	2016	2,363
	2017	2,331
	2018	2,258
	2019	2,296
	2020	2,388
	2021 and thereafter	22,884
	Total	$	36,429
	Facilities rent expense for the three months ended March 31, 2015 and 2014 were $0.6 million and $0.7 million, respectively.
	On June 12, 2013, the Company entered into a lease agreement for two adjacent office, research and development, and manufacturing facilities in Irvine, California.  The premises consist of approximately 129,000 combined square feet. The lease has a 15-year term beginning January 1, 2014 and provides for one optional five year extension. The initial base rent under the lease is $1.9 million per year, payable in monthly installments, and escalates by 3% per year for years 2015 through 2019, and 4% per year for years 2020 and beyond.  The Company received a rent abatement for the first nine months of the lease. These premises replaced the Company's existing Irvine facilities. The terms of this lease agreement provide for $6.8 million of landlord-funded improvements (and certain other allowances) to this facility, in order to best suit the Company's requirements.
	The Company leased two adjacent facilities aggregating approximately 57,000 square feet in Irvine, California, under separate lease agreements where manufacturing was held. The Company exited one of these leases in December 2014 and the other lease in April 2015. The Company also leases an administrative office of approximately 2,900 square feet in Rosmalen, The Netherlands, with lease expiration in December 2015 and renewal at its option.
	(b) Employment Agreements and Retention Plan
	On February 1, 2014, the Company entered into new employment agreements with certain of its executive officers under which payment and benefits would become payable in the event of termination by the Company for any reason other than cause, death or disability or termination by the employee for good reason (collectively, an “Involuntary Termination”) prior to, upon or following a change in control of the Company. The severance payment will generally be in a range of six to eighteen months of the employee’s then current salary for an Involuntary Termination prior to a change in control of the Company, and will generally be in a range of eighteen to twenty-four months of the employee’s then current salary for an Involuntary Termination upon or following a change in control of the Company.
	(c) Legal Matters
	We are from time to time involved in various claims and legal proceedings of a nature we believe are normal and incidental to a medical device business. These matters may include product liability, intellectual property, employment, and other general claims. Such cases and claims may raise complex factual and legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit is brought, and differences in applicable law. We accrue for contingent liabilities when it is probable that a liability has been incurred and the amount can be reasonably estimated. The accruals are adjusted periodically as assessments change or as additional information becomes available.
	LifePort Sciences LLC v. Endologix, Inc.
	On December 28, 2012, LifePort Sciences, LLC ("LifePort") filed a complaint against us in the U.S. District Court, District of Delaware, alleging that certain of our products infringe U.S. Patent Nos. 5,489,295, 6,117,167, 6,302,906, 5,993,481 and 5,676,696, which are alleged to be owned by LifePort. LifePort is seeking an unspecified amount of monetary damages for sale of our products and injunctive relief. We do not believe that we infringe on any of these patents and we intend to vigorously defend against this matter. The case is currently scheduled for trial in April 2016. We do believe, however, that the outcome will not have a material adverse effect on our financial position, results of operations, or cash flow. However, in order to avoid further legal costs and diversion of management resources, it is reasonably possible that we may reach a settlement with LifePort, which could result in a liability. However, we cannot presently estimate the amount, or range, of reasonably possible losses due to the nature of this potential litigation settlement.

Contingently_Issuable_Common_S

Contingently Issuable Common Stock	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Contingently Issuable Common Stock	Contingently Issuable Common Stock
	On October 27, 2010, the Company, entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Nepal Acquisition Corporation, a wholly-owned subsidiary of the Company (“Merger Sub”), Nellix, Inc., certain of Nellix’s stockholders named therein and Essex Woodlands Health Ventures, Inc., as representative of the former Nellix stockholders. On December 10, 2010 (the “Nellix Closing Date”), the Company completed the merger (the “Merger”) of Merger Sub with and into Nellix Inc., a pre-revenue, AAA medical device company pursuant to the terms of the Merger Agreement. The purchase price consisted of 3.2 million shares of the Company's common stock, issuable to the former Nellix stockholders as of the Nellix Closing Date, then representing a value of $19.4 million. Additional payments, solely in the form of shares of the Company's common stock (the “Contingent Payment”), will be made upon the achievement of a revenue milestone and a regulatory approval milestone (collectively, the “Nellix Milestones”).
	The ultimate value of the Contingent Payment will be determined on the date that each Nellix Milestone is achieved. The number of issuable shares will be established using an applicable per share price, which is subject to a ceiling and/or floor, resulting at the closing of the merger in a potential maximum of 10.2 million shares issuable upon the achievement of the Nellix Milestones. As of the Closing Date, the fair value of the Contingent Payment was estimated to be $28.2 million.
	The Merger Agreement provides that, in addition to the shares of common stock of the Company (the “Common Stock”) issued to the former Nellix stockholders at the closing of the Merger, the former Nellix stockholders are entitled to receive shares of the Common Stock if the Company’s sales of one of Nellix’s products (the “Nellix Product”) outside of the United States exceed $10.0 million within a certain time period following the Company’s receipt of CE mark approval for the Nellix Product (the “OUS Milestone”). The aggregate dollar value of the shares of the Common Stock to be issued upon achievement of the OUS Milestone ranged from a high of $24.0 million or 6.9 million shares to a low of $10.0 million or 1.3 million shares. The price per share of the Common Stock to be issued upon achievement of the OUS Milestone was subject to a floor of $3.50 per share and a ceiling of $7.50 per share.
	On June 17, 2014, the Company announced its achievement of the OUS Milestone and the issuance of an aggregate of 2.7 million unregistered shares of the Common Stock (the “OUS Milestone Shares”), plus an amount of cash in lieu of fractional shares, to the former Nellix stockholders. The Company offered and sold the OUS Milestone Shares in reliance upon exemptions from registration pursuant to Section 4(2) under the Securities Act of 1933, as amended (the “Securities Act”). The former Nellix stockholders previously gave representations to the Company regarding their investment intent, experience, financial sophistication, access to information regarding the Company and certain other matters to support the Company’s reasonable belief that it could rely upon the foregoing exemptions from registration pursuant to Section 4(2) of the Securities Act. No underwriting discounts or commissions were or will be paid in conjunction with the issuance of the OUS Milestone Shares. The Company previously filed a Registration Statement on Form S-3 (Registration No. 333-171639) (the “Form S-3”) for the purpose of registering for resale shares of the Common Stock issued or issuable pursuant to the Merger Agreement, including the OUS Milestone Shares. The Securities and Exchange Commission declared the Form S-3 effective on January 18, 2011.
	If the Company receives approval from the FDA to sell the Nellix Product in the United States (the “PMA Milestone”), the Company will issue additional shares of the Common Stock to the former stockholders of Nellix. The dollar value of the shares of the Common Stock to be issued upon achievement of the PMA Milestone will be equal to $15.0 million (less the dollar value of certain cash payments and other deductions). The price per share of the shares of the Common Stock to be issued upon achievement of the PMA Milestone is subject to a stock price floor of $4.50 per share, but not subject to a stock price ceiling.
	As of March 31, 2015 the Company's stock price last closed at $17.07 per share. Thus, had the PMA Milestone been achieved on March 31, 2015 the Contingent Payment would have comprised 1.0 million shares (based on the 30-day average closing stock price ending 5 days prior to the announcement), representing a value of $17.1 million.
	The value of the Contingent Payment is derived using a discounted income approach model, with a range of probabilities and assumptions related to the timing and likelihood of achievement of the PMA Milestone (which include Level 3 inputs - see Note 3(e) and the Company's stock price (Level 1 input) as of the balance sheet date). These varying probabilities and assumptions and changes in the Company's stock price have required fair value adjustments of the Contingent Payment in periods subsequent to the Nellix Closing Date.
	The Contingent Payment fair value will continue to be evaluated on a quarterly basis until milestone achievement occurs, or until the expiration of the "earn-out period," as defined within the Nellix purchase agreement. Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
		Fair Value of Contingently Issuable Common Stock
	December 31, 2014	$	14,600
	Fair Value Adjustment of Contingent Payment for the three months ended March 31, 2015	100
	March 31, 2015	$	14,700

Income_Tax_Expense

Income Tax Expense	3 Months Ended
	Mar. 31, 2015
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income Tax Expense	Income Tax Expense
	The Company applied an estimated annual effective tax rate (“ETR”) approach for calculating a tax provision for interim periods. The Company recorded a expense for income taxes of $0.1 million for the three months ended March 31, 2015. The Company's ETR was (0.8)% for the three months ended March 31, 2015.  The Company's ETR for the three months ended March 31, 2015 differs from the U.S. federal statutory tax rate of 34% primarily as a result of nondeductible expenses (including the Nellix Contingent Payment), state income taxes, foreign income taxes, and the impact of a full valuation allowance on its deferred tax assets.
	The Company has evaluated the available evidence supporting the realization of its deferred tax assets, including the amount and timing of future taxable income, and has determined that it is more likely than not that its net deferred tax assets will not be realized in the U.S. and certain foreign jurisdictions. Due to uncertainties surrounding the realization of the deferred tax assets, the Company maintains a full valuation allowance against substantially all deferred tax assets. If/when the Company determines that it will be able to realize some portion or all of its deferred tax assets, an adjustment to its valuation allowance on its deferred tax assets would have the effect of increasing net income in the period(s) such determination is made.

Description_of_Business_Basis_1

Description of Business, Basis of Presentation, and Operating Segment (Policies)	3 Months Ended
	Mar. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation
	The accompanying Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). These financial statements include the financial position, results of operations, and cash flows of the Company, including its subsidiaries, all of which are wholly-owned. All inter-company accounts and transactions have been eliminated in consolidation. For the three months ended March 31, 2015 and 2014, there were no related party transactions.
	The interim financial data as of March 31, 2015 is unaudited and is not necessarily indicative of the results for a full year. In the opinion of the Company's management, the interim data includes normal and recurring adjustments necessary for a fair presentation of the Company's financial results for the three months ended March 31, 2015. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to SEC rules and regulations relating to interim financial statements.
	The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and Notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2014, filed with the SEC on March 2, 2015.
Operating segment	Operating Segment
	The Company has one operating and reporting segment that is focused exclusively on the development, manufacture, marketing, and sale of EVAR and EVAS product for the treatment of aortic disorders. For the three months ended March 31, 2015, all of the Company's revenue and related expenses were solely attributable to these activities. Substantially all of the Company's long-lived assets are located in the U.S.

Balance_Sheet_Account_Detail_T

Balance Sheet Account Detail (Tables)	3 Months Ended
	Mar. 31, 2015
Balance Sheet Related Disclosures [Abstract]
Property and Equipment	Property and equipment consisted of the following:
		March 31,			December 31,
		2015			2014
	Production equipment, molds, and office furniture	$	13,560		$	12,943
	Computer hardware and software	6,504			6,457
	Leasehold improvements	16,251			15,729
	Construction in progress (software and related implementation, production equipment, and leasehold improvements)	1,188			2,564
	Property and equipment, at cost	$	37,503		$	37,693
	Accumulated depreciation	(12,174		)	(11,997		)
	Property and equipment, net	$	25,329		$	25,696
Schedule of Inventories	Inventories consisted of the following:
		March 31,			December 31,
		2015			2014
	Raw materials	$	8,161		$	6,728
	Work-in-process	7,372			5,946
	Finished goods	19,610			18,651
	Total Inventories	$	35,143		$	31,325
Schedule of Intangible Assets and Goodwill	The following table presents goodwill, indefinite lived intangible assets, finite lived intangible assets, and related accumulated amortization:
		March 31,			December 31,
		2015			2014
	Goodwill (1)	$	28,673		$	28,866
	Intangible assets:
	Indefinite lived intangibles
	Trademarks and trade names	$	2,708		$	2,708
	Finite lived intangibles
	Developed technology (2)	$	40,100		$	40,100
	Accumulated amortization	(382		)	(285		)
	Developed technology, net	$	39,718		$	39,815
	License	$	100		$	100
	Accumulated amortization	(78		)	(71		)
	License, net	$	22		$	29
	Customer relationships (1)	$	429		$	480
	Accumulated amortization (1)	(393		)	(400		)
	Customer relationships, net	$	36		$	80
	Acquired Shonin approval (3)	$	1,000		$	1,000
	Accumulated amortization	(417		)	(167		)
	Acquired Shonin approval, net	$	583		$	833
	Intangible assets (excluding goodwill), net	$	43,067		$	43,465
	(1) Difference in the value between these dates is solely due to a foreign currency translation adjustment.
	(2) Was reclassified in the first quarter of 2013 from in-process research and development to finite lived intangibles, which coincided with the European commercial launch of the product (Nellix EVAS System) associated with this intangible asset. A significant portion of this intangible asset will not begin amortization until the U.S. launch of this product, currently scheduled for 2016.
	(3) Regulatory approval for Intuitrak in Japan acquired through an amendment with a distributor in the fourth quarter of 2014.
Schedule of Expected Amortization Expense	Estimated amortization expense for the five succeeding years and thereafter (which includes amortization of intangible assets which commenced in February 2013 with the commercial launch of the Nellix System in Europe) is as follows:
	Remainder of 2015	$	931
	2016	948
	2017	2,210
	2018	3,689
	2019	4,744
	2020	5,409
	2021 & Thereafter	22,428
	Total	$	40,359
Marketable Securities	Investments in held-to-maturity marketable securities consist of the following at March 31, 2015 and December 31, 2014:
		31-Mar-15
		Amortized			Gross			Gross			Fair Value
		Cost			Unrealized			Unrealized
					Gain			Loss
	Asset backed securities	$	1,473		$	—		$	—		$	1,473
	Agency bonds	3,000			—			(1		)	2,999
	Corporate bonds	5,669			—			(2		)	5,667
	Commercial paper	40,281			7			—			40,288
	Government securities	3,044			—			—			3,044
	Total	$	53,467		$	7		$	(3	)	$	53,471
		31-Dec-14
		Amortized			Gross			Gross			Fair Value
		Cost			Unrealized			Unrealized
					Gain			Loss
	Asset backed securities	$	3,633		$	—		$	—		$	3,633
	Corporate bonds	15,707			—			(8		)	15,699
	Commercial paper	40,531			5			—			40,536
	Total	$	59,871		$	5		$	(8	)	$	59,868
Fair Value Measurements, Recurring and Nonrecurring	The following fair value hierarchy table presents information about each major category of the Company’s assets and liabilities measured at fair value on a recurring basis as of March 31, 2015 and December 31, 2014:
		Fair value measurement at reporting date using:
		Quoted prices in			Significant other			Significant			Total
		active markets for			observable			unobservable
		identical assets			inputs			inputs
		(Level 1)			(Level 2)			(Level 3)
	At March 31, 2015
	Cash and cash equivalents	$	20,183		$	—		$	—		$	20,183
	Contingently issuable common stock	$	—		$	—		$	14,700		$	14,700
	At December 31, 2014
	Cash and cash equivalents	$	26,798		$	—		$	—		$	26,798
	Contingently issuable common stock	$	—		$	—		$	14,600		$	14,600

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	Stock-based compensation expense included in cost of goods sold and operating expenses during the three months ended March 31, 2015 and 2014, was as follows:
		Three Months Ended
		March 31,
		2015		2014
	Cost of goods sold	$	248	$	208
	Operating expenses:
	Research and development	228		161
	Clinical and regulatory affairs	185		(103		)
	Marketing and sales	749		538
	General and administrative	801		809
	Total operating expenses	$	1,963	$	1,405
	Total	$	2,211	$	1,613

Net_Income_Loss_Per_Share_Tabl

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted
		Three Months Ended
		March 31,
		2015				2014
	Net income (loss)	$	(11,213	)		$	5,295
	Weighted average shares- basic	67,263				63,405
	Weighted average shares- diluted	67,263				66,017
	Net income (loss) per share- basic	$	(0.17	)		$	0.08
	Net income (loss) per share- diluted	$	(0.17	)		$	0.08
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding Company securities, using the treasury stock method, were excluded from the above calculations of net income loss per share because their impact would have been anti-dilutive:
		Three Months Ended
		March 31,
		2015			2014
	Common stock options	1,813			1,153
	Restricted stock awards	135			—
	Restricted stock units	234			—
	Total	2,182			1,153
	As discussed in Note 6, in December 2013, the Company issued $86.3 million aggregate principal amount of 2.25% convertible senior notes due 2018 (the “Notes”) in an underwritten public offering. Upon any conversion, the Notes may be settled, at the Company’s election, in cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock. For purposes of calculating the maximum dilutive impact, it is presumed that the Notes will be settled in common stock with the resulting potential common shares included in diluted earnings per share if the effect is more dilutive. The effect of the conversion of the Notes is excluded from the calculation of diluted income (loss) per share because the impact of these securities would be anti-dilutive. The potential dilutive effect of these securities is shown in the chart below:
		Three Months Ended
		March 31,
		2015			2014
	Conversion of the Notes	3,588			3,588

Revenue_by_Geographic_Region_T

Revenue by Geographic Region (Tables)	3 Months Ended
	Mar. 31, 2015
Geographic Areas, Revenues from External Customers [Abstract]
Revenue by Geographic Region	The Company's revenue by geographic region, was as follows:
		Three Months Ended
		March 31,
		2015			2014
	United States	$	25,134	68.50%	$	23,988	72.10%
	Europe	$	7,246	19.80%	$	6,585	19.80%
	Rest of World ("ROW"):
	Latin America	$	2,039	5.60%	$	918	2.80%
	Asia/Pacific	2,252		6.10%	1,773		5.30%
	Total ROW	$	4,291	11.70%	$	2,691	8.10%
	Revenue	$	36,671	100.00%	$	33,264	100.00%

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Contractual Obligation, Fiscal Year Maturity Schedule	Future minimum payments by year under non-cancelable leases with initial terms in excess of one year were as follows as of March 31, 2015:
	Remainder of 2015	$	1,909
	2016	2,363
	2017	2,331
	2018	2,258
	2019	2,296
	2020	2,388
	2021 and thereafter	22,884
	Total	$	36,429

Contingently_Issuable_Common_S1

Contingently Issuable Common Stock (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions by Acquisition, Fair Value of Contingent Consideration	Adjustments to the fair value of the Contingent Payment are recognized within other income (expense) in the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss).
		Fair Value of Contingently Issuable Common Stock
	December 31, 2014	$	14,600
	Fair Value Adjustment of Contingent Payment for the three months ended March 31, 2015	100
	March 31, 2015	$	14,700

Description_of_Business_Basis_2

Description of Business, Basis of Presentation, and Operating Segment (Details)	3 Months Ended
	Mar. 31, 2015
	segment
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments	1
Number of reportable segments	1

Balance_Sheet_Account_Detail_P

Balance Sheet Account Detail (Property and Equipment) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$37,503,000		$37,693,000
Accumulated depreciation	-12,174,000		-11,997,000
Property and equipment, net	25,329,000		25,696,000
Depreciation expense	1,100,000	500,000
Production equipment, molds, and office furniture
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	13,560,000		12,943,000
Computer hardware and software
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	6,504,000		6,457,000
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	16,251,000		15,729,000
Construction in progress (software and related implementation, production equipment, and leasehold improvements)
Property, Plant and Equipment [Line Items]
Property and equipment, at cost	$1,188,000		$2,564,000

Balance_Sheet_Account_Detail_I

Balance Sheet Account Detail (Inventories) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Balance Sheet Related Disclosures [Abstract]
Raw materials	$8,161	$6,728
Work-in-process	7,372	5,946
Finished goods	19,610	18,651
Inventories	$35,143	$31,325

Balance_Sheet_Account_Detail_G

Balance Sheet Account Detail (Goodwill and Intangible Assets) (Details) (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Thousands, unless otherwise specified
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Goodwill	$28,673	[1]	$28,866	[1]
Total	40,359
Intangible assets (excluding goodwill), net	43,067		43,465
Developed technology
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles	40,100	[2]	40,100	[2]
Accumulated amortization	-382		-285
Total	39,718		39,815
License
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles	100		100
Accumulated amortization	-78		-71
Total	22		29
Customer relationships
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles	429	[1]	480	[1]
Accumulated amortization	-393		-400
Total	36		80
Acquired Shonin approval
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Finite lived intangibles	1,000	[3]	1,000	[3]
Accumulated amortization	-417		-167
Total	583		833
Trademarks and trade names
Goodwill, Finite-lived, and Indefinite-lived Intangible Assets [Line Items]
Indefinite lived intangibles	$2,708		$2,708
[1]	Difference in the value between these dates is solely due to a foreign currency translation adjustment.
[2]	Was reclassified in the first quarter of 2013 from in-process research and development to finite lived intangibles, which coincided with the European commercial launch of the product (Nellix EVAS System) associated with this intangible asset. A significant portion of this intangible asset will not begin amortization until the U.S. launch of this product, currently scheduled for 2016.
[3]	Regulatory approval for Intuitrak in Japan acquired through an amendment with a distributor in the fourth quarter of 2014.

Balance_Sheet_Account_Detail_A

Balance Sheet Account Detail (Amortization) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Balance Sheet Related Disclosures [Abstract]
Amortization expense	$400,000	$100,000
Remainder of 2015	931,000
2016	948,000
2017	2,210,000
2018	3,689,000
2019	4,744,000
2020	5,409,000
2021 & Thereafter	22,428,000
Total	$40,359,000

Balance_Sheet_Account_Detail_H

Balance Sheet Account Detail (Held to Maturity Marketable Securities) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	$53,467	$59,871
Gross Unrealized Gain	7	5
Gross Unrealized Loss	3	8
Fair Value	53,471	59,868
Asset backed securities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	1,473	3,633
Gross Unrealized Gain	0	0
Gross Unrealized Loss	0	0
Fair Value	1,473	3,633
Agency bonds
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	3,000
Gross Unrealized Gain	0
Gross Unrealized Loss	1
Fair Value	2,999
Corporate bonds
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	5,669	15,707
Gross Unrealized Gain	0	0
Gross Unrealized Loss	2	8
Fair Value	5,667	15,699
Commercial paper
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	40,281	40,531
Gross Unrealized Gain	7	5
Gross Unrealized Loss	0	0
Fair Value	40,288	40,536
Government securities
Schedule of Held-to-maturity Securities [Line Items]
Amortized Cost	3,044
Gross Unrealized Gain	0
Gross Unrealized Loss	0
Fair Value	3,044
Corporate debt securities
Schedule of Held-to-maturity Securities [Line Items]
Gross Unrealized Loss	3
Fair Value	$11,200
Held-to-maturity debt securities held	8

Balance_Sheet_Account_Detail_F

Balance Sheet Account Detail (Fair Value Measurements) (Details) (Fair Value, Measurements, Recurring, USD $)	Mar. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$20,183,000	$26,798,000
Contingently issuable common stock	14,700,000	14,600,000
Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	20,183,000	26,798,000
Contingently issuable common stock	0	0
Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Contingently issuable common stock	0	0
Fair value of long-term debt	87,800,000	84,500,000
Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Contingently issuable common stock	$14,700,000	$14,600,000

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$2,211	$1,613
Cost of goods sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	248	208
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	228	161
Clinical and regulatory affairs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	185	-103
Marketing and sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	749	538
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	801	809
Total operating expenses
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated stock-based compensation expense	$1,963	$1,405

Net_Income_Loss_Per_Share_Deta

Net Income (Loss) Per Share (Details) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 10, 2013
Earnings Per Share, Basic and Diluted [Abstract]
Net loss	($11,213)	$5,295
Weighted average shares- basic	67,263,000	63,405,000
Weighted average shares- diluted	67,263,000	66,017,000
Net income (loss) per share-basic (in dollars per share)	($0.17)	$0.08
Net income (loss) per share-diluted (in dollars per share)	($0.17)	$0.08
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Shares included in the Calculation of Earnings Per Share Because Their Impact was Dilutive	0	2,612,000
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	2,182,000	1,153,000
Convertible notes	71,270		70,407
Potential Dilutive Effect of Securities [Abstract]
Conversion of the Notes	3,588,000	3,588,000
Convertible Debt
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Convertible notes				$86,300
Stated interest rate			2.25%
Common stock options
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Shares included in the Calculation of Earnings Per Share Because Their Impact was Dilutive	0	2,027,000
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	1,813,000	1,153,000
Restricted Stock
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Shares included in the Calculation of Earnings Per Share Because Their Impact was Dilutive	0	152,000
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	135,000	0
Restricted stock units
Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]
Shares included in the Calculation of Earnings Per Share Because Their Impact was Dilutive	0	433,000
Securities Excluded from Calculations of Earnings Per Share Because Impact Would Have Been Anti-Dilutive [Abstract]
Outstanding securities used in calculations	234,000	0

Credit_Facilities_Details

Credit Facilities (Details) (USD $)	0 Months Ended		12 Months Ended	3 Months Ended	12 Months Ended
	Dec. 10, 2013	Dec. 03, 2013	Dec. 31, 2013	Mar. 31, 2015	Dec. 31, 2014
Line of Credit Facility [Line Items]
Convertible notes				$71,270,000	$70,407,000
Deferred Finance Costs, Noncurrent, Net				2,300,000
Payments of Derivative Issuance Costs	7,400,000
Revolving Credit Facility | Wells Fargo Bank
Line of Credit Facility [Line Items]
Aggregate maximum borrowing capacity		20,000,000
Debt Covenant, Minimum Current Ratio		2
Revolving Credit Facility | Wells Fargo Bank | Debt Instrument, Measurement Period One
Line of Credit Facility [Line Items]
Debt Covenant, Maximum Operating Loss		13,500,000
Revolving Credit Facility | Wells Fargo Bank | Debt Instrument, Measurement Period Two
Line of Credit Facility [Line Items]
Debt Covenant, Maximum Operating Loss		23,000,000
Revolving Credit Facility | Wells Fargo Bank | Debt Instrument, Measurement Period Three
Line of Credit Facility [Line Items]
Debt Covenant, Maximum Operating Loss		35,000,000
Debt Covenant, Maximum Annual Capital Expenditures			6,000,000
Revolving Credit Facility | Wells Fargo Bank | Debt Instrument, Measurement Period Four
Line of Credit Facility [Line Items]
Debt Covenant, Maximum Annual Capital Expenditures				3,000,000
Letter of Credit | Wells Fargo Bank
Line of Credit Facility [Line Items]
Aggregate maximum borrowing capacity		7,500,000
Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Debt Instrument, Face Amount	86,300,000
Stated interest rate	2.25%
Proceeds from Convertible Debt	82,600,000
Stock Issued During Period, Shares, Conversion of Convertible Securities	41.6051
Redemption Price, Percentage	100.00%
Debt Default, Violation Or Event Of Default, Declaration By Note Holders, Percentage	25.00%
Fair Value Disclosure	66,900,000
Beneficial Conversion Feature	19,300,000
Unamortized Discount	3,700,000
Debt Instrument, Convertible, Conversion Price	$24.04
Derivative, Cap Price	29.02
Debt Instrument, Redemption, Period One | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Threshold Trading Days	20
Threshold Consecutive Trading Days	30 days
Threshold Percentage of Stock Price Trigger	130.00%
Redemption Price, Percentage	100.00%
Debt Instrument, Redemption, Period Two | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Threshold Trading Days	20
Threshold Consecutive Trading Days	30 days
Threshold Percentage of Stock Price Trigger	98.00%
Threshold Business Days	5
Threshold Consecutive Business Days	5 years
Other Assets | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Unamortized Discount	2,900,000
Additional Paid-in Capital | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Unamortized Discount	800,000
Minimum | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Debt Instrument, Periodic Payment, Interest					5,700,000
Maximum | Convertible Senior Notes Issued December, 2013 | Convertible Debt
Line of Credit Facility [Line Items]
Debt Instrument, Periodic Payment, Interest					$6,900,000

Revenue_by_Geographic_Region_D

Revenue by Geographic Region (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$36,671	$33,264
Geographic Concentration Risk | Sales
Schedule of Revenue by Geographic Region [Line Items]
Revenue	36,671	33,264
Concentration risk percentage	100.00%	100.00%
Geographic Concentration Risk | Sales | United States | Direct
Schedule of Revenue by Geographic Region [Line Items]
Revenue	25,134	23,988
Concentration risk percentage	68.50%	72.10%
Geographic Concentration Risk | Sales | Europe
Schedule of Revenue by Geographic Region [Line Items]
Revenue	7,246	6,585
Concentration risk percentage	19.80%	19.80%
Geographic Concentration Risk | Sales | Latin America | Distributor
Schedule of Revenue by Geographic Region [Line Items]
Revenue	2,039	918
Concentration risk percentage	5.60%	2.80%
Geographic Concentration Risk | Sales | Asia/Pacific | Distributor
Schedule of Revenue by Geographic Region [Line Items]
Revenue	2,252	1,773
Concentration risk percentage	6.10%	5.30%
Geographic Concentration Risk | Sales | Total ROW | Distributor
Schedule of Revenue by Geographic Region [Line Items]
Revenue	$4,291	$2,691
Concentration risk percentage	11.70%	8.10%

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	0 Months Ended	1 Months Ended		3 Months Ended
	Jun. 12, 2013	Dec. 31, 2014	Jun. 30, 2013	Mar. 31, 2015	Mar. 31, 2014
	option	lease	letters_of_credit
	sqft
	facility
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Remainder of 2015				$1,909,000
2016				2,363,000
2017				2,331,000
2018				2,258,000
2019				2,296,000
2020				2,388,000
2021 and thereafter				22,884,000
Total				36,429,000
Rent expense				600,000	700,000
Number of facilities	2
Aggregate square feet	129,000
Term of contract	15 years
Number of renewal options	1
Renewal term	5 years
Initial base rent	1,900,000
LandLord-funded improvements	$6,800,000
Number of letters of credit			2
Number of leases exited		1
Operating Leases, Future Minimum Payments Due, Base Rent Increases [Abstract]
2015	3.00%
2016	3.00%
2017	3.00%
2018	3.00%
2019	3.00%
2020 and beyond	4.00%
Manufacturing Facility
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Aggregate square feet	57,000
Building
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Aggregate square feet	2,900

Contingently_Issuable_Common_S2

Contingently Issuable Common Stock (Details) (USD $)	3 Months Ended		0 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 10, 2010	Jun. 17, 2014	Jun. 16, 2014
Fair Value of Contingently Issuable Common Stock [Roll Forward]
31-Dec-14	$14,600,000
Fair Value Adjustment of Contingent Payment for the three months ended March 31, 2015	100,000	-11,800,000
31-Mar-15	14,700,000
Nelix Milestones
Business Acquisition [Line Items]
Number of shares contingently issuable			10.2
Estimated fair value of Contingent payment			28,200,000
OUS Milestone
Business Acquisition [Line Items]
Purchase price common shares				2.7
OUS Milestone | Common Stock
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, Low	10,000,000
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Shares, Low	1.3
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High	24,000,000
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Shares, High	6.9
OUS Milestone | Common Stock | Minimum
Business Acquisition [Line Items]
Business Acquisition, Share Price					$3.50
OUS Milestone | Common Stock | Maximum
Business Acquisition [Line Items]
Business Acquisition, Share Price					$7.50
PMA Milestone
Business Acquisition [Line Items]
Common shares value			15,000,000
Number of shares contingently issuable	1
Closing stock price	$17.07
Contingent consideration, at fair value hypothetical value	17,100,000
PMA Milestone | Maximum
Business Acquisition [Line Items]
Business Acquisition, Share Price			$4.50
Nellix
Business Acquisition [Line Items]
Purchase price common shares			3.2
Common shares value			$19,400,000

Income_Tax_Expense_Details

Income Tax Expense (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Current Income Tax Expense (Benefit), Continuing Operations [Abstract]
Income tax expense	$92	$216
Effective income tax rate	-0.80%
Federal statutory income tax rate	34.00%